Division of Infectious Diseases, Multi-Organ Transplant Program, University of Toronto, University Health Network, Toronto, Ontario, Canada.
Department of Pharmacy, University Health Network, Toronto, Ontario, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
J Heart Lung Transplant. 2019 Sep;38(9):963-971. doi: 10.1016/j.healun.2019.06.007. Epub 2019 Jun 19.
Bronchiolitis obliterans syndrome (BOS) is a major limitation in the long-term survival of lung transplant recipients (LTRs). However, the risk factors in the development of BOS remain undetermined. We conducted an international cohort study of LTRs to assess whether Aspergillus colonization with large or small conidia is a risk factor for the development of BOS.
Consecutive LTRs from January 2005 to December 2008 were evaluated. Rates of BOS and associated risk factors were recorded at 4 years. International Society of Heart and Lung Transplantation criteria were used to define fungal and other infections. A Cox proportional-hazards-model was constructed to assess the association between Aspergillus colonization and the development of BOS controlling for confounders.
A total of 747 LTRs were included. The cumulative incidence of BOS at 4 years after transplant was 33% (250 of 747). Additionally, 22% of LTRs experienced Aspergillus colonization after transplantation. Aspergillus colonization with either large (hazard ratio [HR] = 0.6, 95% confidence interval [CI] = 0.3-1.2, p = 0.12) or small conidia (HR = 0.9, 95% CI = 0.6-1.4, p = 0.74) was not associated with the development of BOS. Factors associated with increased risk of development of BOS were the male gender (HR = 1.4, 95% CI = 1.1-1.8, p = 0.02) and episodes of acute rejection (1-2 episodes, HR = 1.5, 95% CI = 1.1-2.1, p = 0.014; 3-4 episodes, HR = 1.6, 95% CI = 1.0-2.6, p = 0.036; >4 episodes, HR = 2.2, 95% CI = 1.1-4.3, p = 0.02), whereas tacrolimus use was associated with reduced risk of BOS (HR = 0.6, 95% CI = 0.5-0.9, p = 0.007).
We conclude from this large multicenter cohort of lung transplant patients, that Aspergillus colonization with large or small conidia did not show an association with the development of BOS.
闭塞性细支气管炎综合征(BOS)是肺移植受者(LTR)长期生存的主要限制因素。然而,BOS 发展的危险因素仍未确定。我们对 LTR 进行了一项国际队列研究,以评估大或小分生孢子的曲霉定植是否是 BOS 发展的危险因素。
评估 2005 年 1 月至 2008 年 12 月期间的连续 LTR。在 4 年时记录 BOS 的发生率和相关危险因素。国际心肺移植协会的标准用于定义真菌和其他感染。使用 Cox 比例风险模型来评估曲霉定植与 BOS 发展之间的关联,同时控制混杂因素。
共纳入 747 例 LTR。移植后 4 年时 BOS 的累积发生率为 33%(747 例中有 250 例)。此外,22%的 LTR 在移植后发生曲霉定植。大分生孢子(HR=0.6,95%置信区间[CI]=0.3-1.2,p=0.12)或小分生孢子(HR=0.9,95%CI=0.6-1.4,p=0.74)的曲霉定植与 BOS 的发展无关。与 BOS 发展风险增加相关的因素包括男性(HR=1.4,95%CI=1.1-1.8,p=0.02)和急性排斥反应发作(1-2 次发作,HR=1.5,95%CI=1.1-2.1,p=0.014;3-4 次发作,HR=1.6,95%CI=1.0-2.6,p=0.036;>4 次发作,HR=2.2,95%CI=1.1-4.3,p=0.02),而他克莫司的使用与 BOS 风险降低相关(HR=0.6,95%CI=0.5-0.9,p=0.007)。
我们从这项大型多中心肺移植患者队列研究中得出结论,大分生孢子或小分生孢子的曲霉定植与 BOS 的发展没有关联。